JoanRButtertonMD
Internal Medicine • Boston, MAInfectious Disease
Assistant Clinical Professor of Medicine, Massachusetts General Hospital
Are you Dr. Butterton?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 64 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit St
Brb 5
Boston, MA 02114Phone+1 617-768-8730Fax+1 617-768-8731- Is this information wrong?
Summary
- Dr. Joan Butterton, MD is an internist in Boston, Massachusetts. She is currently licensed to practice medicine in Massachusetts. She is an Assistant Clinical Professor of Medicine at Massachusetts General Hospital.
Education & Training
Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1988 - 1994- Massachusetts General HospitalResidency, Internal Medicine, 1985 - 1988
Harvard Medical SchoolClass of 1985
Certifications & Licensure
MA State Medical License 1987 - 2023
Publications & Presentations
PubMed
- Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for...Ignacio Martin-Loeches, Jean-François Timsit, Marin H Kollef, Richard G Wunderink, Nobuaki Shime, Martin Nováček, Ülo Kivistik, Álvaro Réa-Neto, Christopher J Bruno, J...> ;The Journal of Antimicrobial Chemotherapy. 2022 Mar 31
- 60 citationsRandomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19.Arribas, J., Bhagani, S., Lobo, S., Khaertynova, I., Mateu, L., Fishchuk, R., Park, W., Hussein, K., Kim, S., Ghosn, J., Brown, M., Zhang, Y., Gao, W., Assaid, C., Gro...> ;NEJM Evidence. 2022 Feb 1
- 45 citationsPhase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults.Caraco, Y., Crofoot, G., Moncada, P., Galustyan, A., Musungaie, D., Payne, B., Kovalchuk, E., Gonzalez, A., Brown, M., Williams-Diaz, A., Gao, W., Strizki, J., Grobler...> ;NEJM Evidence. 2022 Feb 1
- Join now to see all
Press Mentions
Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 InfectionDecember 6th, 2021- Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of People Living with HIV-1November 18th, 2021
- Merck Presents New Data from Ongoing Phase 2a Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of Investigational, Once-Monthly, Oral Islatravir for HIV-1 Prevention at IAS 2021July 20th, 2021
- Join now to see all
Grant Support
- New Animal Model For EHEC Pathogenesis And PreventionNational Institute Of Diabetes And Digestive And Kidney Diseases2000–2004
- Mucosal Immunity To Cholera Vectored EHEC AntigensNational Institute Of Allergy And Infectious Diseases1998
- Cholera-Vectored Delivery System For Pertussis AntigensNational Institute Of Allergy And Infectious Diseases1996–1998
- Iron-Regulated Virulence Factors In Vibrio CholeraeNational Institute Of Allergy And Infectious Diseases1989–1992
